ÂÜÀòÂÒÂ×

Mark Treherne is the Chairperson at Monument Therapeutics, Talisman Therapeutics Limited, Ubiquigent Ltd, NuVision Biotherapies Ltd, and Cell Guidance Systems. Mark is also a Non-Executive Director at Domain Therapeutics. Previously, Mark served as a Consultant and later Chairperson at CYCLOFLUIDIC LIMITED and as Chief Executive at Cellesce Ltd, Avilex Pharma ApS, and the Life Sciences Organisation. Mark holds a Ph.D. in Pharmacology from the University of Cambridge, an M.Phil. in Pharmacology, and a B.Sc. in Physiology and Pharmacology from the University of St Andrews.